Tandem Diabetes Care, Inc. $TNDM Position Lowered by Paradice Investment Management LLC

Key Points

• Paradice Investment Management LLC trimmed its stake in Tandem Diabetes Care by 5.4% in Q4, selling 118,723 shares and leaving it with 2,077,745 shares (about 3.06% of TNDM) worth roughly $45.67 million, making the stock its second-largest holding (~8.9% of the fund).
• Tandem's latest quarter beat estimates with $290.38 million in revenue (up 15.1% YoY) and EPS of ($0.01) versus a ($0.05) consensus, but the company remains unprofitable with a negative net margin (~20.17%) and negative return on equity (~68.23%).
• The Street's consensus is a "Hold" with a $29.22 price target; the stock has a market cap of about $1.42 billion and a 52-week range of $9.98–$29.65.

Paradice Investment Management LLC decreased its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,077,745 shares of the medical device company's stock after selling 118,723 shares during the quarter. Tandem Diabetes Care makes up about 8.9% of Paradice Investment Management LLC's portfolio, making the stock its 2nd biggest holding. Paradice Investment Management LLC owned approximately 3.06% of Tandem Diabetes Care worth $45,669,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC raised its stake in Tandem Diabetes Care by 36.7% during the third quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company's stock worth $44,811,000 after purchasing an additional 991,649 shares during the period. Freestone Grove Partners LP purchased a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $22,706,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Tandem Diabetes Care by 3.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,481,953 shares of the medical device company's stock valued at $17,991,000 after buying an additional 50,646 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Tandem Diabetes Care during the 4th quarter worth approximately $26,988,000. Finally, Baillie Gifford & Co. increased its holdings in shares of Tandem Diabetes Care by 2.2% during the 4th quarter. Baillie Gifford & Co. now owns 1,145,516 shares of the medical device company's stock worth $25,178,000 after buying an additional 24,921 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Shares of TNDM stock opened at $20.68 on Friday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. The firm has a market cap of $1.42 billion, a P/E ratio of -6.74 and a beta of 1.74. The firm's 50 day moving average price is $21.75 and its 200-day moving average price is $20.01. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. The firm had revenue of $290.38 million during the quarter, compared to the consensus estimate of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The firm's revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS. As a group, equities research analysts predict that Tandem Diabetes Care, Inc. will post -0.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on TNDM. Mizuho set a $22.00 price objective on Tandem Diabetes Care and gave the company a "neutral" rating in a report on Friday, February 20th. Morgan Stanley raised their target price on Tandem Diabetes Care from $23.00 to $25.00 and gave the stock an "equal weight" rating in a research note on Monday, March 2nd. Stifel Nicolaus lifted their target price on Tandem Diabetes Care from $20.00 to $22.00 and gave the company a "hold" rating in a research report on Friday, February 20th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tandem Diabetes Care in a research note on Wednesday, January 21st. Finally, UBS Group reiterated a "neutral" rating and set a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $29.22.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.